Cancer News and Research

Latest Cancer News and Research

Study unravels the complex interplay of the UPS in cancer development and treatment

A new review published in Genes & Diseases explores the pivotal role of the ubiquitin-proteasome system (UPS) in regulating the tumor microenvironment (TME) and driving cancer progression. The study provides novel insights into how ubiquitination and deubiquitination impact tumor cells, immune responses, and potential therapeutic strategies for cancer treatment.

24 Feb 2025

Unveiling the role of FAM20C in disease and cancer treatment

A new review published in Genes & Diseases explores the multifaceted role of FAM20C, a Golgi protein kinase, in disease progression.

23 Feb 2025

Aging isn’t just in your genes—your environment plays a bigger role, study shows

Study explores the relative contributions of genetics and environmental factors to aging and premature mortality. It highlights how the exposome—lifetime environmental exposures—shapes disease risks, with socioeconomic status, smoking, and lifestyle choices emerging as key aging determinants.

23 Feb 2025

Medicare patients with cancer often receive aggressive treatment over supportive care

Many Medicare patients with advanced cancer receive potentially aggressive treatment at the expense of supportive care, according to a study that analyzed Medicare records.

22 Feb 2025

New intervention helps reduce ultra-processed food intake and improve health

Most dietary programs are designed to help people achieve weight loss or adhere to U.S. nutrition guidelines, which currently make no mention of ultra-processed foods (UPFs).

22 Feb 2025

Study reveals gaps in palliative care for patients with advanced cancer

Despite considerable efforts to improve the quality of end-of-life care in the United States, a new retrospective study led by American Cancer Society (ACS) researchers revealed that close to half of patients with advanced cancer received potentially aggressive care at the end-of-life at the expense of supportive care.

22 Feb 2025

New photosensitizer shows promise in treating colorectal cancer

Colorectal cancer (CRC) is a highly malignant disease that readily metastasizes to vital organs. Many strategies have been employed for clinical CRC therapy.

22 Feb 2025

Exploring the dual role of LKB1 in tumor suppression and promotion

Mutations in serine-threonine kinase 11 (STK11) and liver kinase B1 (LKB1) are associated with disease progression in Peutz-Jeghers syndrome (PJS), which can progress to cancer.

22 Feb 2025

Discovery paves way for new hepatitis B treatment

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center (MSK), Weill Cornell Medicine, and The Rockefeller University identified a vulnerability that opens the door to new treatments.

22 Feb 2025

New computational tool iDOMO improves prediction of drug synergy

Researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases.

22 Feb 2025

Development of lymphoma following CAR-T cell therapy

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

22 Feb 2025

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy.

22 Feb 2025

Study finds lack of consensus on how to treat chronic non-cancer pain

Chronic pain is complex and difficult to treat. Prescribing opioid pain medications has become controversial but may help some patients.

22 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025